Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
arcticnovartis

  • Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population health

  • Scales program footprint from 11 countries to more than 30 by 2030, including across five cities in the U.S.

  • Builds on pilot programs that demonstrated significant increase in control rates for high blood pressure in pilot settings
/by
Working with communities to close gaps in heart disease and cancer care

Working with communities to close gaps in heart disease and cancer care
metzgma4

/by
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
arcticnovartis

  • Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1
  • 40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1
  • Fabhalta granted priority review by FDA for traditional approval

Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN).

/by
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
arcticnovartis

– Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases
   
– Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deeper pathway suppression
   
– Exl-111 would complement existing Novartis portfolio in allergy with potential to improve both symptom control and convenience
  

/by
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
arcticnovartis

  • New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented

  • Long-term Cosentyx® data build on extensive body of evidence supporting continuous use in hidradenitis suppurativa (HS) and psoriasis

  • Additional Cosentyx data in HS include indirect comparison of efficacy and safety vs bimekizumab 

/by
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
arcticnovartis

  • Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer 
  • The lead asset, SNV4818, currently in a Phase 1/2 clinical study, is designed to selectively target PI3Kα mutations in breast cancer while sparing wild-type PI3Kα, thus reducing unwanted side effects and improving tolerability
/by
Building the Future: Novartis Innovation Lab – AI, Game Studio, XR & Emerging Tech

Building the Future: Novartis Innovation Lab – AI, Game Studio, XR & Emerging Tech
halesmi2

/by
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
arcticnovartis

  • Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 

  • HS often emerges around puberty, underscoring importance of early diagnosis and intervention with biologics to help reduce long-term disease burden4-6 

  • Approval marks fourth pediatric indication for Cosentyx, reinforcing its robust safety and efficacy profile1 
/by
Bringing proteins together to take cancer apart

Bringing proteins together to take cancer apart
halesmi2

/by
Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut

Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut
arcticnovartis

  • Die Aktionärinnen und Aktionäre genehmigten die 29. Dividendenerhöhung in Folge. Für 2025 wird die Dividende auf CHF 3.70 (+5,7%) je Aktie erhöht, was einer Rendite von 3,0% entspricht¹

  • Die Aktionärinnen und Aktionäre bestätigten Giovanni Caforio als Vorsitzenden des Verwaltungsrats sowie alle weiteren Mitglieder des Verwaltungsrats die zur Wiederwahl standen. Charles Swanton wurde zum neuen Mitglied des Verwaltungsrats gewählt.
/by